SEC Form 4 · accession 0000899243-18-016878
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley J Bolzon Ph.D.
Director
Period of report
Jun 15, 2018
Accepted (ET)
Jun 15, 2018 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3,F1 | $59.31 | Jun 15, 2018 | A | 30,000 | A | — | Jun 15, 2028 | Common Shares | 30,000 | 30,000 | I |
Explanation of responses
- F1This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018.
- F2One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC.
- F3(Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.